tolvaptan has been researched along with deamino arginine vasopressin in 9 studies
| Studies (tolvaptan) | Trials (tolvaptan) | Recent Studies (post-2010) (tolvaptan) | Studies (deamino arginine vasopressin) | Trials (deamino arginine vasopressin) | Recent Studies (post-2010) (deamino arginine vasopressin) |
|---|---|---|---|---|---|
| 967 | 172 | 786 | 4,396 | 516 | 1,016 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Krahn, TA; Mount, DB | 1 |
| Fujiki, H; Hirose, T; Miyazaki, T; Ohmoto, K | 1 |
| Bichet, DG; Blumenfeld, JD; Coller, B; Mauer, A; Smith, B; Tepler, J | 1 |
| Kettritz, R; Luft, FC | 1 |
| Arima, H; Banno, R; Fujisawa, H; Goto, M; Iwama, S; Izumida, H; Kiyota, A; Nakashima, K; Ochiai, H; Ogawa, K; Oiso, Y; Suga, H; Sugimura, Y; Suzuki, H; Takagi, H; Takeuchi, S | 1 |
| Hew-Butler, T; Hummel, J; Rider, BC; Verbalis, JG | 1 |
| Harris, PC; Hommerding, CJ; Hopp, K; Torres, VE; Wang, X; Ye, H | 1 |
| Alvear-Perez, R; Bonnet, D; De Mota, N; Estéoulle, L; Flahault, A; Girault-Sotias, PE; Iturrioz, X; Keck, M; Llorens-Cortes, C; Ramanoudjame, SM | 1 |
2 review(s) available for tolvaptan and deamino arginine vasopressin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Disorders of fluid and electrolyte balance].
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Deamino Arginine Vasopressin; Humans; Hyperkalemia; Hypernatremia; Hyponatremia; Inappropriate ADH Syndrome; Membrane Potentials; Morpholines; Osmolar Concentration; Potassium; Randomized Controlled Trials as Topic; Sodium; Spiro Compounds; Survival Rate; Tolvaptan; Water-Electrolyte Imbalance | 2011 |
1 trial(s) available for tolvaptan and deamino arginine vasopressin
| Article | Year |
|---|---|
Characterization of the effects of the vasopressin V2 receptor on sweating, fluid balance, and performance during exercise.
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biomarkers; Deamino Arginine Vasopressin; Double-Blind Method; Exercise; Female; Hormone Antagonists; Humans; Male; Middle Aged; Neurophysins; Osmolar Concentration; Physical Endurance; Plasma Volume; Protein Precursors; Receptors, Vasopressin; Running; Signal Transduction; Sodium; Sweat; Sweat Glands; Sweating; Thirst; Time Factors; Tolvaptan; Vasopressins; Water-Electrolyte Balance; Weight Loss; Young Adult | 2014 |
6 other study(ies) available for tolvaptan and deamino arginine vasopressin
| Article | Year |
|---|---|
Hyponatremia: case vignettes.
Topics: Adult; Aged; Benzazepines; Deamino Arginine Vasopressin; Female; Humans; Hyponatremia; Male; Middle Aged; Saline Solution, Hypertonic; Tolvaptan; Treatment Outcome | 2009 |
Chronic hyponatremia impairs memory in rats: effects of vasopressin antagonist tolvaptan.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Avoidance Learning; Benzazepines; Body Water; Brain; Deamino Arginine Vasopressin; Hyponatremia; Male; Memory; Memory Disorders; Motor Activity; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, Vasopressin; Sodium; Tolvaptan | 2010 |
Tolvaptan inhibition of desmopressin effects on coagulation factors in a patient with decreased von Willebrand factor and polycystic kidney disease.
Topics: Adult; Benzazepines; Blood Coagulation; Blood Coagulation Factors; Deamino Arginine Vasopressin; Down-Regulation; Humans; Male; Polycystic Kidney Diseases; Tolvaptan; von Willebrand Factor | 2011 |
Minocycline prevents osmotic demyelination associated with aquaresis.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Aquaporin 4; Astrocytes; Behavior, Animal; Benzazepines; Biomarkers; Brain; Chemokines; Cytokines; Cytoprotection; Deamino Arginine Vasopressin; Demyelinating Diseases; Disease Models, Animal; Diuresis; Hyponatremia; Intracranial Hemorrhages; Male; Matrix Metalloproteinases; Minocycline; Neuroprotective Agents; Osmosis; Rats, Sprague-Dawley; Saline Solution, Hypertonic; Sodium; Therapeutics; Time Factors; Tolvaptan; Water-Electrolyte Balance | 2014 |
Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model.
Topics: Animals; Antidiuretic Agents; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cell Line, Tumor; Cell Membrane; Cyclic AMP; Deamino Arginine Vasopressin; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microsatellite Repeats; Models, Genetic; Polycystic Kidney, Autosomal Dominant; Somatostatin; Tolvaptan; TRPP Cation Channels | 2015 |
A metabolically stable apelin-17 analog decreases AVP-induced antidiuresis and improves hyponatremia.
Topics: Amino Acid Sequence; Animals; Apelin; Apelin Receptors; Arginine Vasopressin; Blood Glucose; Blood Pressure; Cell Line; Colforsin; Cyclic AMP; Deamino Arginine Vasopressin; Disease Models, Animal; Diuresis; Electrolytes; Half-Life; Hyponatremia; Kidney Tubules, Collecting; Male; Mice; Models, Biological; Myocardial Contraction; Peptides; Phosphorylation; Rats, Sprague-Dawley; Tolvaptan | 2021 |